Fonseca VA - Search Results

1

Insulin resistance, diabetes, hypertension, and renin-angiotensin system inhibition: reducing risk for cardiovascular disease.

Fonseca VA. Fonseca VA. J Clin Hypertens (Greenwich). 2006 Oct;8(10):713-20; quiz 721-2. doi: 10.1111/j.1524-6175.2006.05583.x. J Clin Hypertens (Greenwich). 2006. PMID: 17028485 Free PMC article. Review.

2

Effects of thiazolidinediones on cardiovascular risk factors.

Gouda BP, Asnani S, Fonseca VA. Gouda BP, et al. Among authors: fonseca va. Compr Ther. 2002 Winter;28(4):200-6. doi: 10.1007/s12019-002-0018-8. Compr Ther. 2002. PMID: 12506489 Review.

3

Management of the insulin resistance syndrome.

Desouza C, Gilling L, Fonseca V. Desouza C, et al. Curr Diab Rep. 2001 Oct;1(2):140-7. doi: 10.1007/s11892-001-0026-6. Curr Diab Rep. 2001. PMID: 12643110 Review.

4

Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease.

Fonseca VA. Fonseca VA. Am J Cardiol. 2003 Aug 18;92(4A):50J-60J. doi: 10.1016/s0002-9149(03)00616-7. Am J Cardiol. 2003. PMID: 12957327 Review.

5

Nontraditional risk factors for cardiovascular disease in diabetes.

Fonseca V, Desouza C, Asnani S, Jialal I. Fonseca V, et al. Endocr Rev. 2004 Feb;25(1):153-75. doi: 10.1210/er.2002-0034. Endocr Rev. 2004. PMID: 14769830 Review.

6

Role of insulin secretagogues and insulin sensitizing agents in the prevention of cardiovascular disease in patients who have diabetes.

Jawa AA, Fonseca VA. Jawa AA, et al. Among authors: fonseca va. Cardiol Clin. 2005 May;23(2):119-38. doi: 10.1016/j.ccl.2004.06.001. Cardiol Clin. 2005. PMID: 15694742 Review.

7

Potential cardiovascular benefits of insulin sensitizers.

Kunhiraman BP, Jawa A, Fonseca VA. Kunhiraman BP, et al. Among authors: fonseca va. Endocrinol Metab Clin North Am. 2005 Mar;34(1):117-35. doi: 10.1016/j.ecl.2004.11.005. Endocrinol Metab Clin North Am. 2005. PMID: 15752925 Review.

8

Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy.

Jawa A, Nachimuthu S, Pendergrass M, Asnani S, Fonseca V. Jawa A, et al. J Clin Endocrinol Metab. 2006 Jan;91(1):31-5. doi: 10.1210/jc.2005-1632. Epub 2005 Oct 11. J Clin Endocrinol Metab. 2006. PMID: 16219712 Clinical Trial.

9

Diabetes treatments have differential effects on nontraditional cardiovascular risk factors.

Fonseca VA, Theuma P, Mudaliar S, Leissinger CA, Clejan S, Henry RR. Fonseca VA, et al. J Diabetes Complications. 2006 Jan-Feb;20(1):14-20. doi: 10.1016/j.jdiacomp.2005.05.009. J Diabetes Complications. 2006. PMID: 16389162 Clinical Trial.

10

The metabolic syndrome, hyperlipidemia, and insulin resistance.

Fonseca VA. Fonseca VA. Clin Cornerstone. 2005;7(2-3):61-72. doi: 10.1016/s1098-3597(05)80069-9. Clin Cornerstone. 2005. PMID: 16473262 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

361 results

Search Page

Filters